Guangdong Hybribio Biotech Co.,Ltd.

Shenzhen Stock Exchange 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd. Net Income for the year ending December 31, 2023: USD 19.79 M

Guangdong Hybribio Biotech Co.,Ltd. Net Income is USD 19.79 M for the year ending December 31, 2023, a -92.09% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Guangdong Hybribio Biotech Co.,Ltd. Net Income for the year ending December 31, 2022 was USD 250.11 M, a 86.50% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Net Income for the year ending December 31, 2021 was USD 134.11 M, a 141.38% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Net Income for the year ending December 31, 2020 was USD 55.56 M, a 162.68% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Net Income for the year ending December 31, 2019 was USD 21.15 M, a 27.51% change year over year.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd.

CEO Ms. Jianyu Wang
IPO Date April 13, 2017
Location Hong Kong
Headquarters 50 Bonham Strand
Employees 2,669
Sector Healthcare
Industries
Description

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.

Similar companies

002030.SZ

Daan Gene Co., Ltd.

USD 0.73

-4.26%

300244.SZ

Dian Diagnostics Group Co.,Ltd.

USD 1.44

-2.25%

300482.SZ

Guangzhou Wondfo Biotech Co.,Ltd

USD 3.07

0.63%

300406.SZ

Beijing Strong Biotechnologies, Inc.

USD 1.82

0.98%

603882.SS

Guangzhou Kingmed Diagnostics Group Co., Ltd.

USD 3.37

-1.70%

StockViz Staff

February 3, 2025

Any question? Send us an email